Vedanta Biosciences has raised $68 million to take a microbiome candidate into phase 3. The biotech also used the series D update to reveal the failure of its Bristol Myers Squibb checkpoint inhibitor alliance to generate data to support further development.

Coave Therapeutics has added €21.2 ($25.0 million) million to its series B round, setting the French biotech up to move a gene therapy against PDE6b inherited retinal dystrophies toward pivotal trials.

Turnstone Biologics kicked off the year with a buyout that brought a tumor-infiltrating lymphocyte (TIL) platform under its roof. Now, it’s banking $80 million from a laundry list of backers to get its leading TIL program, along with its most advanced cancer-killing virus treatment, through the clinic.

Novartis is culling an eye disease asset but has got an FDA approval date for its troubled The Medicines Company heart drug, while also sending off for review its Bosulif-rivalling blood cancer hopeful.

A month after filing for Canadian approval for its lead ALS candidate, Amylyx Pharmaceuticals has picked up $135 million to bankroll a potential commercial launch and support a pipeline of other candidates for neurodegenerative diseases, including the one causing a stir this summer: Alzheimer’s disease.

Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma’s collaboration with his former employers.

Shares in Ardelyx are in freefall after the FDA found a series of “deficiencies” with Ardelyx’ application for the kidney disease hopeful tenapanor.

Panakès has raised a €150 million ($177 million) fund that will extend its focus beyond medtech and into biotech. The VC shop will mainly use the money to invest in the series A rounds of European biotech and medtech startups, with a particular focus on its home country of Italy.

The Empire State’s biggest biotech Regeneron Pharmaceuticals is plotting a hefty investment to beef up R&D in Tarrytown. And it plans to add a significant number of jobs along the way.

Months after finally revealing its first weapons against cancer, Erasca has pulled off a $300 million IPO. The proceeds will propel an SHP2 inhibitor and an ERK inhibitor through the clinic and get at least one more prospect into human trials.